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inhibition of human pancreatic cancer cells
Nikolaos Ioannou1, Alan M Seddon1, Angus Dalgleish2, David Mackintosh1 and Helmout Modjtahedi1*Abstract
Background: Aberrant expression and activation of the IGF-IR have been reported in a variety of human cancers
and have been associated with resistance to HER targeted therapy. In this study, we investigated the effect of
simultaneous targeting of IGF-IR and HER (erbB) family, with NVP-AEW541 and afatinib, on proliferation of
pancreatic cancer cells.
Methods: The sensitivity of a panel of human pancreatic cancer cell lines to treatment with NVP-AEW541 used
alone or in combination with afatinib, anti-EGFR antibody ICR62, and cytotoxic agents was determined using the
Sulforhodamine B colorimetric assay. Growth factor receptor expression, cell-cycle distribution and cell signalling
were determined using flow cytometry and western blot analysis.
Results: All pancreatic cancer cell lines were found to be IGF-IR positive and NVP-AEW541 treatment inhibited the
growth of the pancreatic cancer cell lines with IC50 values ranging from 342 nM (FA6) to 2.73 μM (PT45).
Interestingly, of the various combinations examined, treatment with a combination of NVP-AEW541 and afatinib
was superior in inducing synergistic growth inhibition of the majority of pancreatic cancer cells.
Conclusion: Our results indicate that co-targeting of the erbB (HER) family and IGF-IR, with a combination of
afatinib and NVP-AEW541, is superior to treatment with a single agent and encourages further investigation in vivo
on their therapeutic potential in IGF-IR and HER positive pancreatic cancers.
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Despite major advances in cancer diagnosis and therapy
in the last few decades, pancreatic cancer remains one of
the most fatal types of human cancer with the mean sur-
vival rate of less than 6 months [1,2]. In 2012, pancreatic
cancer is estimated to be the ninth most commonly
diagnosed cancer (43,920) but the fourth leading cause
of cancer deaths (37,390) after lung, colorectal and
breast cancers in the USA [3]. Worldwide, pancreatic
cancer was responsible for an estimated 266,000 deaths
in 2008 [4].* Correspondence: H.Modjtahedi@kingston.ac.uk
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reproduction in any medium, provided the orSince the early 1980s, aberrant expression and activa-
tion of Receptor Tyrosine Kinases (RTKs) such as the
ErbB (HER) family of receptors have been shown to be
implicated in several human malignancies and in some
cases have been associated with a poor prognosis [5-8].
The ErbB (also called HER or EGFR) family of receptors is
one of the best characterized RTK and consists of four fam-
ily members namely; EGFR (HER-1), ErbB2 (HER-2), ErbB3
(HER-3) and ErbB4 (HER-4) [9,10]. Activation of the HER
family members following ligand binding, leads to the acti-
vation of several downstream signalling pathways including
the Ras-Raf-mitogen activated protein kinase (MAPK),
phosphatidylinositol 3 kinase protein (PI3K)/AKT pathway,
PLC- γ-protein kinase C (PKC) and signal transducers and
activators of transcription (STAT) pathway. Deregulation ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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proliferation, motility, evasion of apoptosis and angiogenesis
and these are some of the hallmarks of human cancers
[9,11,12]. To date, several HER targeting agents have been
approved for treatment of human cancers including meta-
static colorectal cancer [anti-EGFR monoclonal antibodies
(mAbs) cetuximab and panitumumab], non-small cell lung
cancer [tyrosine kinase inhibitors (TKIs) gefitinib and
erlotinib] ,early stage and metastatic breast (anti-HER-2
mAbs trastuzumab and pertuzumab, and dual EGFR/HER2
TKI lapatinib), head and neck (cetuximab), metastatic stom-
ach cancers (trastuzumab) and pancreatic (erlotinib). How-
ever, despite these advances, many patients simply do not
respond to or acquire resistance to therapy with the HER
inhibitors [8].
The Insulin-like Growth Factor receptor (IGF-IR) is
another very well characterized RTK and the main medi-
ator of the biological action of IGF-I and IGF-II [13,14].
The IGF signalling network includes the IGF-I and IGF-
II ligands, insulin, the cell surface receptors IGF-IR,
IGF-IIR and the Insulin receptor (IR) as well as a group
of regulatory IGF binding proteins (IGFBPs) [14-16].
The IGF-IR signalling axis is implicated in the regulation
of a number of cellular processes including cell growth,
survival and cell differentiation, and its aberrant activa-
tion has been associated with increased cell proliferation,
reduced apoptosis, transformation, angiogenesis and
increased cell motility and resistance to chemotherapy
and radiotherapy in several types of human cancers
[14,17,18]. As a result, the IGF-IR network has emerged
as an attractive target for the development of new thera-
peutic strategies and a number of small molecule IGF-IR
TKIs and anti-IGF-IR mAbs have been developed which
are at different stages of preclinical evaluations and clin-
ical trials in several types of human malignancies. In
addition, recent studies have demonstrated that IGF-IR
is implicated in resistance to anti-HER targeted therapy
and consequently, simultaneous targeting of HER family
members and IGF-IR may lead to a superior therapeutic
effect in cancer patients.
We have recently reported the superiority of afatinib,
an irreversible erbB family blocker, compared to the anti
HER monoclonal antibody (mAb) ICR62 and first gener-
ation TKI erlotinib in inhibiting the growth of a panel of
human pancreatic tumour cells [19]. The aim of this
study was to investigate the sensitivity of the same panel
of pancreatic cancer cell lines to treatment with an IGF-IR
TKI, NVP-AEW541[20], when used alone or in combin-
ation with afatinib, anti-EGFR mAb ICR62 or gemcitabine.
In addition, we investigated the effect of these inhibitors
on the phosphorylation of HER receptors, IGF-IR and
downstream molecules such as MAPK and AKT and
whether there was any association between the expression
of the receptor and sensitivity to treatment.Methods
Tumour cell lines
A panel of 7 human pancreatic cancer cell lines was
used in this study including BxPC3, PT45, MiaPACA2,
PANC-1, AsPc-1, Capan-1 and FA6 as well as control
EGFR overexpressing head and neck cancer cell line
HN5 and breast carcinoma cell line MCF-7. AsPc-1 and
Capan-1 cell lines were kindly provided by Dr. Charlotte
Edling (Blizard Institute of Cell and Molecular Science,
Barts and The London School of Medicine and Dentis-
try). All cell lines were cultured routinely at 37°C in a
humidified atmosphere (5% CO2) in either DMEM
(Sigma – Aldrich, UK) (Miapaca-2, Panc-1, HN5 and
MCF-7) or RPMI-1640 medium (Sigma – Aldrich, UK)
(BxPC3, PT45, AsPc-1, Capan-1 and FA6) supplemented
with 10% Foetal Bovine Serum (PAA, UK), antibiotics
penicillin (50 units/mL), streptomycin (0.05 mg/mL) and
neomycin (0.1 mg/mL) as described previously [19].
RPMI-1640 medium was supplemented with 2mM Glu-
tamine (Sigma - Aldrich, UK).
Antibodies and other reagents
MAb ICR62 (IgG2b) was raised against the external do-
main of the EGFR on the breast cancer cell line MDA-
MB468 as described previously [21]. The primary mouse
anti-IGF-IR antibody used in this study for flow cytometry
was purchased from R&D Systems (Abingdon, UK). Sec-
ondary FITC-conjugated rabbit anti-mouse mAb STAR9B
was obtained from AbD Serotec (Kidlington, UK) while
gemcitabine was acquired from Healthcare at Home (UK).
PI3K inhibitor LY294002 and MAPKK/MEK inhibitor
U0126 were purchased from Cell signaling (UK). The anti-
IGF-IR TKI NVP-AEW541 and pan-HER inhibitor afatinib
were kindly provided by Novartis (Basel, Switzerland) and
Boehringer Ingelheim respectively (Vienna, Austria) [20,22].
Mouse antibodies against HER-2, HER-3, HER-4, p-IGF-IR
(Tyr1165/1166) and anti-IGF-IR rabbit antibody were
obtained from Santa Cruz, UK. Mouse antibody against β-
actin was purchased from Cell Signalling, UK, while mouse
anti-EGFR antibody from Sigma-Aldrich, UK. Rabbit anti-
bodies against AKT, MAPK, phospho-MAPK (Thr202/
Tyr204), p-HER-3 (Tyr1289), p-HER-2 (Tyr1221/1222)
and phospho EGFR (Tyr1086) were purchased from Cell
Signalling,UK while anti-phospho AKT (S473) rabbit anti-
body was obtained from Biosource, UK.
Determination of cell surface expression of growth factor
receptors
The cell surface expression of IGF-IR was assessed by
flow cytometry as described previously [19]. Briefly,
about 1 million cells were incubated for 1 hour by rota-
tion at 4°C, with the primary antibody or control
medium alone. Cancer cells were then washed three
times by centrifugation and incubated for 1 hour by
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IgG STAR9B (AbD Serotec, UK). A minimum of 10.000
events were recorded following excitation with an argon
laser at 488 nm using the FL-1 detector (525 nm) of a
BD FACsCalibur flow cytometer (Becton Dickinson Ltd,
UK). Mean fluorescence intensity values were calculated
using the CellQuest Pro software (Becton Dickinson Ltd,
UK) and compared with those of negative controls (no
primary antibody).
Cell growth studies
The effect of the various agents, on the growth of
human cancer cell lines was investigated using the
Sulforhodamine B (SRB; Sigma – Aldrich, UK) colori-
metric assay as described previously [19]. Briefly, 5 × 103
tumour cells/well were seeded in 100 μL of growth
medium supplemented with 2% FBS in a 96-well plate.
After 4 hours incubation at 37°C, 100 μL aliquots of
doubling dilutions of the agents were added to triplicate
wells. When cells in control wells (no treatment) were al-
most confluent, cells were fixed with 10% trichloroacetic
acid (Fisher Scientific, UK) and stained with 0.4% SRB in
1% acetic acid. SRB stain was solubilised with 10 mM
Tris-base (Fisher Scientific, UK) and the absorbance of
each well was measured at 565 nm using an Epoch plate
reader (Biotek, UK). Growth as a percentage of control
was determined as described previously [19]. IC50 values
were calculated using the Gen5 software (Biotek, UK).
Determination of combination index
Interactions between the different agents when used in
combination were assessed, using the combination index
(CI) as described by Chou and Talalay [23]. For each
combination the two drugs were mixed at their 4 × IC50
followed by 8 doubling dilutions. CI <0.9 indicates a syn-
ergistic effect while CI between 0.90 -1.10 denotes an
additive effect. CI >1.1 indicates antagonistic effects.
Data analysis was performed using the Calcusyn soft-
ware (Biosoft, UK).
Cell cycle distribution analysis
The effect of NVP-AEW541 on the cell cycle distribution
of the cancer cell lines was investigated using flow
cytometry. Briefly, approximately 2.5 × 105 cells were see-
ded to 25 cm2 flasks containing 10 mL of 2% FBS growth
medium and the inhibitors at different concentrations or
control medium. Once the cells containing only medium
were almost confluent, treated cells were harvested and
pooled together with the supernatant and washed three
times with cold PBS by centrifugation. The final cell pellet
was re-suspended in 200 μL of cold PBS, fixed by the
addition of 70% ethanol and incubated overnight at 4°C.
Tumour cells were incubated with PI/RNAse mix (Becton
Dickinson Ltd, UK) for 35 min at room temperature. Aminimum of 10.000 events were recorded by excitation
with an argon laser at 488nm using the FL-3 detector
(620 nm) of a BD FACsCalibur flow cytometer (Becton
Dickinson Ltd, UK) and analysed using the CellQuest
Pro software (Becton Dickinson Ltd, UK).
Western blot analysis
Cancer cells were grown to near confluency in 6-well
culture plates containing 5 mL of 10% FBS RPMI growth
medium. Cells were washed once with 5 ml of RPMI/
0.5% FBS and incubated in 5 mL of RPMI/0.5% FBS
containing no inhibitor, NVP-AEW541 (400 nM), afati-
nib (400 nM) or ICR62 (200 nM) for 24 hours at 37°C.
Following incubation with the inhibitors, cells were
stimulated with 20 nM of EGF (R&D systems), IGF-I,
IGF-II, NRG-1(Cell signaling, UK) or Insulin (Austral
Biologicals, California, USA) for 15 min. Cancer cells
were lysed using 400 μL of lithium dodecyl sulfate (LDS)
lysis buffer (Invitrogen, UK) containing protease inhibi-
tor cocktail (Sigma-Aldrich, UK) and cell lysates were
heated at 90°C for 5 min. Protein samples (30 μg) were
separated on 4% to 12% Bis-Tris gels (Invitrogen, UK)
and transferred to polyvinylidene difluoride (PVDF)
membranes (Invitrogen, UK). The PVDF membranes
were probed with antibodies at optimal concentrations
according to the manufacturer’s instructions. The specific
signals were detected using the WesternBreeze chemilu-
minescence kit (Alkaline phosphatase conjugated second-
ary antibody) (Invitrogen, UK). Results were visualized
using the GenGnome5 imaging system (Syngene, UK).
Statistical analysis
The unpaired two-tailed Student’s t-test was used for
comparing mean values between two groups. Data are
presented as mean ± SD. P < 0.05 was considered
statistically significant.
Results
IGF-IR expression in pancreatic cancer cells
We have reported recently the cell surface expression
levels of HER family members on seven human pancre-
atic cancer cell lines and found all seven cancer cell lines
to be positive for both EGFR and HER-2 , negative for
HER-4 while expressing extremely low or undetectable
levels of HER-3 [19]. Here, we determined the expres-
sion levels of IGF-IR in the same panel of pancreatic
cancer cell lines using flow cytometry. All pancreatic
tumour cell lines were found to be positive for IGF-IR,
with MFIs ranging from 4.2 (FA6) to 22.7 (PT45) (adjusted
to negative control) (Figure 1). In the majority of the
pancreatic cancer cell lines examined, the IGF-IR ex-
pression levels were similar to the IGF-IR expression level
in the control MCF-7 breast tumour cell line (MFI = 19.6)
(Figure 1).
Figure 1 Expression of IGF-IR in human pancreatic tumour cell lines assessed by Flow Cytometry as described in the Materials and
methods. Results are expressed as Mean Fluorescent Intensity (MFI) values. Breast cancer cell line MCF-7 was used as a positive control.
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treatment with HER family growth factors, IGF-I, IGF-II
and insulin
We determined the growth response of human pancre-
atic cancer cell lines to treatment with EGFR ligands
(EGF, TGFα, AR, Epigen), HER-3 and HER-4 ligand
NRG-1, EGFR and HER-4 ligands ( HB-EGF, Epiregulin
and BTC) , IGF-IR ligands (IGF-I and IGF-II) and insu-
lin at a concentration of 40 nM for 72 h using the SRB
assay (Figure 2). For this assay, cells were grown in
medium containing 2% FBS as in growth inhibition stud-
ies with other agents. We have shown previously that, at
nM concentrations, EGFR ligands inhibit the growth of
EGFR overexpressing tumour cell lines in vitro [24]. To con-
firm the bioactivity of exogenous HER ligands, we examined
their effects on the growth of EGFR overexpressing HN5
cells. All HER ligands, except NRG-1, inhibited the growth
of HN5 cells in vitro (Figure 2). In addition, with the excep-
tion of BxPC3 and AsPc-1 cell lines which exhibited signifi-
cant growth response to NRG-1 (BxPc3: 36% increase
compared to the control, p<0.01, AsPc-1: 19% increase
compared to the control, p<0.01), the majority of pancreatic
tumour cell lines did not respond to treatment with the ex-
ogenous HER ligands or exhibited very low increase in cell
proliferation (Figure 2). Interestingly AsPc-1 was the only
cell line which exhibited increased growth after treatment
with epigen (18.5%, p<0.01). Of all cell lines examined here,
only BxPc3,AsPc1, Capan-1 and PT45 cell lines demon-
strated significant increase in growth (p<0.01) after treat-
ment with IGF-I, IGF-II or insulin (Figure 2).
Growth response of human pancreatic tumour cells to
treatment with NVP-AEW541 as a single agent or in
combination with gemcitabine, afatinib and ICR62
We have reported recently the effect of afatinib, erlotinib,
ICR62 and gemcitabine on the growth of pancreaticcancer cell lines [19]. Of these agents gemcitabine
exhibited the highest anti-proliferative activity with IC50
values at the low nanomolar range while afatinib with a
range of IC50 values from 11nM to 1.37 μM demonstra-
ted a higher anti-tumour activity compared to first gene-
ration EGFR TKI erlotinib [19]. Here we investigated the
growth response of the same panel of pancreatic cancer
cell lines to treatment with NVP-AEW541 an IGF-IR TKI.
Of 7 human pancreatic tumour cell lines examined, FA6
cells were the most sensitive cell line to treatment with
NVP-AEW541 with an IC50 value of 342 nM (Figure 3,
Table 1). The IC50 values for the rest of the cell lines
ranged from 897 nM (ASPC1) to 2.73 μM (PT45).
Median effect analysis showed that a combination of
NVP-AEW541 with gemcitabine led to a synergistic or
additive growth inhibition of 4 out of 7 human pancre-
atic tumour cell lines (Table 2). We found no enhance-
ment of growth inhibition following treatment with a
combination of ICR62 with NVP-AEW541 (data not
shown). Interestingly, with the exception of PT-45, the
combination of the IGF-IR inhibitor NVP-AEW541 with
afatinib was superior to that of NVP-AEW541 with
gemcitabine leading to synergistic growth inhibition of
all pancreatic cancer cell lines (Table 2, Figure 4). How-
ever, this was statistically significant in four cell lines.
In order to investigate the response of the pancreatic
cancer cell lines to direct inhibition of RAS/RAF/MAPK
and PI3K/AKT signalling cascades as well as their de-
pendency on these pathways, we determined the growth
response of these cell lines to treatment with the PI3K
inhibitor LY294002 and MAPKK/MEk inhibitor U0126.
Both inhibitors were found to be less effective at inhibiting
the growth of pancreatic cancer cell lines compared to
IGF-IR inhibitor NVP-AEW541, with IC50s ranging from
2.3 μM (Capan-1) to 13.7 μM (PANC1) for MAPKK in-
hibitor and 5.5 μM (AsPc-1) to 11.3 μM (PANC1) for the
Figure 2 Effect of HER family and IGF-IR growth factors on the growth of human pancreatic cancer cell lines as percentage of control
growth (*, p<0.05, **, p<0.01). Cells were treated with 40 nM of EGF, TGFα, AR, Epigen, HB-EGF, Epiregulin, BTC, NRG-1, IGF-I, IGF-II or Insulin for
72 h in growth medium supplemented with 2% FBS. Results are expressed as percentage of control cells (no treatment) calculated as described
in the Materials and Methods.
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Figure 3 Effect of doubling dilutions of NVP-AEW541 (A), PI3K inhibitor (B) and MAPK inhibitor (C), on the growth of human pancreatic cancer
cell lines. Tumour cells were grown in the presence of doubling dilutions of the agents or medium alone until control cells (no treatment) were
confluent. Cell proliferation was calculated as percentage of control cell growth, as described in the Materials and Methods. Each point represents the
mean ±s.d of triplicate samples.
Table 1 IC50 values for NVP-AEW541, PI3K and MAPKK inhibitors in pancreatic cancer cell lines as assessed by the SRB
colorimetric assay
ICell line NVPAEW541 MAPKK inh PI3K inh
BxPc-3 1.54 (1.37–1.74) μM 3.5 (2.77–4.1) μM 6.9 (6.12–7.96) μM
AsPc-1 0.897 (0.79–0.92) μM 4.9 (4.52–5.42) μM 5.5 (5.12–6.06) μM
FA-6 0.342 (0.26–0.36) μM 11.5 (10.15–13.08) μM 9.1 (8.53–9.74) μM
PANC-1 2.66 (1.8–3.2) μM 13.7 (12.38–15.2) μM 11.3 (10.28–12.59) μM
Capan-1 0.969 (0.9–1.04) μM 2.3 (2.23–2.51) μM 5.9 (5.56–6.39) μM
MiaPaca-2 1.13 (1.01–1.38) μM 3.5 (3.08–4.05) μM 6 (5.69–6.5) μM
PT45 2.73 (2.57–2.87) μM 7.7 (6.97–8.53) μM 8 (7.54–8.52) μM
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Table 2 Mean combination index values of NVP-AEW541 plus gemcitabine or afatinib in pancreatic cancer cell lines
(three independent experiments)
Cell line Mean Combination index (range, effect)
NVP-AEW541+GEM p-value NVP-AEW541+Afatinib p-value
BxPc-3 0.96 (0.92–1.08, Additive) p=0.54 0.34 (0.29–0.44, Synergism) p<0.05
AsPc-1 0.91 (0.86–0.95, Additive) p<0.05 0.75 (0.68–0.84, Moderate Synergism) p<0.05
FA-6 1.22 (1.07–1.33, Moderate antagonism) p<0.05 0.8 (0.68–0.94, Moderate Synergism) p=0.057
PANC-1 0.7 (0.56–0.84, Synergism) p<0.05 0.73 (0.61–0.86, Moderate Synergism) p<0.05
Capan-1 1.43 (1.31–1.52, Moderate antagonism) p<0.05 0.9 (0.81–1.05, Slight Synergism/Additive) p=0.34
MiaPaca-2 1.14 (1.02–1.27, Slight antagonism) p=0.11 0.84 (0.78–0.91, Moderate Synergism) p<0.05
PT45 1.09 (0.92–1.23, Additive) p=0.36 1.44 (Moderate antagonism) p<0.05
Interpretation of the results was based on the proposed descriptions for presenting the degrees of antagonism or synergism by Calcusyn software. P values
indicate level of statistical significance compared with a combination index value of 1.
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cell lines to PI3K inhibition were also found to be resistant
to anti-MAPKK treatment (Table 1, Figure 3B,C).
Cell-cycle distribution analyses
We used flow cytometry in order to determine the effect of
NVP-AEW541 (IC70 concentration) on the cell cycle distri-
bution of the pancreatic cancer cell lines. We have reported
recently that treatment with gemcitabine increased the-20
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Figure 4 The effect of doubling dilutions (starting at 4xIC50 value fol
AEW541 and afatinib compared to single treatment, in (A) BxPc3 , (B)percentage of cells in the sub-G1 and S phase while afatinib
increased the proportion of cells in the sub-G1 and this was
accompanied by a decrease in the population of cells
in G0/G1 [19]. Similarly, an increase in the sub-G1
fraction, indicative of apoptosis, was observed in the
majority of cell lines following NVP-AEW541 treat-
ment and this was statistically significant in FA6,
AsPC-1, PT45 and Capan-1 cells (Table 3). An increase
in the percentage of cells in G0/G1 phase wastion 
Afatinib
NVP-
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Afatinib+NV
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tion 
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lowed by 8 doubling dilutions) of the combination of NVP-
AsPc-1 cell lines.
Table 3 Effect of NVP-AEW541 (IC70) on the cell cycle
distribution of pancreatic cancer cell lines
Cell line/treatment Sub-G1 G0/G1 S G2/M
BxPc3
Control 7.7±1.4 55.6±2.3 25.4±5 10.8±1.8
NVP-AEW541 7.9±2.7 69.7±4.5* 15.7±2.9 6.2±1.1
AsPC-1
Control 1±0.02 46.1±0.3 31.8±0.2 19.5±0.1
NVP-AEW541 3.9±0.2* 47.1±0.4 35.7±1.5 14±2.6
Capan-1
Control 3.8±0.3 50.6±2.5 25.5±3.1 18.6±1.1
NVP-AEW541 7±0.2* 53.6±1.3 23±1.8 15.1±1.4
PT45
Control 2.3±0.6 74.4±4.3 12.3±2.8 10.1±1
NVP-AEW541 10.2±2.7* 59.8±1.4* 19.7±4.8 9.9±2.4
Miapaca-2
Control 4.6±2.6 76.1±2.2 10±1.3 8.6±0.5
NVP-AEW541 5.5±2.7 81±1.3 9.4±0.8 4.5±3.7
PANC1
Control 5.6±1.5 48.3±4.6 11.6±0.1 32.7±4.7
NVP-AEW541 9.3±0.5 72.4±2.1* 12.1±0.3 4.9±0.4*
FA6
Control 13.8±2 48.3±3.1 25.4±4.8 11.2±0.4
NVP-AEW541 36.8±2.8* 33.2±1.2* 22.2±1.3 6.9±2.2
Each population is expressed as percentage of gated cells (mean of three
independent experiments ± S.D).* depicts statistically significant difference
(p<0.05) compared to control values.
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and this increase was statistically significant in BxPc3
and PANC1 (Table 3).
Effect of HER and IGF-IR ligands in the presence or
absence of inhibitors on downstream cell signaling
molecules
First we determined the effect of EGF and IGF-I on the
phosphorylation of AKT and MAPK in all pancreatic
cancer cell lines included in this study and in all cell
lines, with the exception of FA6 cells, EGF primarily
induced to the activation of MAPK while it had low or
no effect on AKT phosphorylation. In contrast, IGF-I
was more potent in inducing the activation of AKT,
while having no or minimal effect on MAPK phosphor-
ylation (Figure 5).
Next, we examined the effect of EGF, IGF-I, IGF-II, in-
sulin and NRG1 on the activation of downstream signaling
pathways in BxPc3 cell line in the presence or absence of
afatinib, NVP-AEW541 or mAb ICR62 (Figure 6A). BxPc3
cell line was selected as the most appropriate model for
investigating cell signaling events since the combination
of afatinib with NVP-AEW541 exhibited the highestsynergistic effect in these cells (lower CI value) (Table 2).
In addition, BxPc3 cell line was positive for all HER family
members and IGF-IR with the exception of HER-4 [19].
Of the HER ligands, EGF induced phophorylation of
EGFR and MAPK while NRG1 induced phosphorylation
of HER-3 and both of MAPK and AKT in BxPC-3 cells
and these effects were blocked completely by afatinib
(Figure 6A, afatinib). In addition, treatment with IGF-IR
ligands increased the level of p-IGF-IR and pAKT but
not pMAPK. At 400 nM NVP-AEW541 inhibited the
IGF-IR ligands induced phosphorylation of both IGF-IR
and AKT but not completely (Figure 6A, NVP-AEW541).
Next we investigated the effect of the above mentioned
ligands in downstream signaling in the presence or ab-
sence of NVP-AEW541 in FA6 cells which was the most
sensitive cell line to treatment with this agent. Inte-
restingly, in contrast to BxPc3 cells, NVP-AEW541 (at
400 nM) inhibited completely the ligand-induced phos-
phorylation of IGF-IR and Akt. The basal levels of
pMAPK were found to be higher in the FA6 cell line
compared to BxPC3 cells and this was not increased fur-
ther following treatment with IGF-IR or HER ligands
(Figure 6B).
Finally, we determined whether afatinib and NVP-
AEW541, when used alone or in combination, have the
same effects in BxPc3 cells grown at optimal conditions
(i.e. medium containing 10% FBS). Only afatinib downregu-
lated the basal levels of pMAPK . In addition, it was also
more potent compared to NVP-AEW541 at downregula-
ting of pAKT. However, only the combination of these two
inhibitors (i.e. afatinib plus NVP-AEW541) led to complete
downregulation of the pAKT basal levels (Figure 6C).
Discussion
Despite significant advances in the understanding of
cancer biology during recent decades, pancreatic cancer
remains one of the deadliest types of human cancer [1-3].
Since the introduction of gemcitabine in 1996, which is
currently the gold standard for the treatment of advanced
pancreatic cancer, only the EGFR TKI erlotinib has gained
FDA approval for the treatment of patients with metastatic
pancreatic cancer in combination with gemcitabine [25].
This combination resulted in a modest, but statistically sig-
nificant survival benefit however, many patients simply do
not respond or acquire resistance following a short course
of therapy [25,26]. Recent studies have demonstrated that
IGF-IR is implicated in resistance to anti-HER targeted
therapy and that simultaneous targeting of both IGF-IR
and EGFR or IGF-IR and HER-2 may lead to a superior
therapeutic effect compared to treatment with the single
agent in breast and glioblastoma, prostate and colorectal
cancer cells [27-36].
To date, the number of studies investigating the effect
of IGF-IR inhibitor NVP-AEW541, in pancreatic cancer
Figure 5 Effect of IGF-I and EGF 20 nM (for 15 min) on downstream signaling pathways in all pancreatic cancer cell lines used in this
study. Cells were grown to near-confluency in 10% FBS growth followed by 24 h incubation in 0.1% FBS growth medium at 37°C. Following that,
cells were stimulated with 20 nM of EGF and IGF-I for 15 min. Cells were lysed, protein samples were separated by SDS-PAGE, transferred onto
PVDF membranes and probed with the antibodies of interest.
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the first study investigating the therapeutic potential of
this approach in pancreatic cancer using a pan-HER
bocker (afatinib) and IGF-IR TKI NVP-AEW541. We have
reported recently the superiority of afatinib compared to
our anti-EGFR mAb ICR62 and erlotinib in inhibiting the
growth of a panel of human pancreatic cancer cell lines.
As a single agent, afatinib inhibited the growth of all
pancreatic cancer cell lines with IC50 values ranging from
11 nM (BxPC-3) to 1.37 μM (FA6) [19]. Interestingly,
BxPC-3, which is the only one carrying a wild-type K-Ras
gene, was the most sensitive cell line to treatment with
HER inhibitors [19]. In addition, we found that treatment
with a combination of afatinib and gemcitabine resulted in
the synergistic growth inhibition of the majority of human
pancreatic cancer cells (BxPC-3, AsPc-1, FA6, PANC-1
and Capan-1) [19]. In this study, we investigated the sensi-
tivity of the same panel of pancreatic cancer cells to
treatment with NVP-AEW541 when used alone or in
combination with gemcitabine, ICR62 or afatinib. We
found NVP-AEW541 to inhibit the growth of all pan-
creatic cancer cell lines with IC50 values ranging from
342 nM (FA6) to 2.73 μM (PT-45) (Figure 3, Table 1).
Western blot analysis revealed that, NVP-AEW541
inhibited completely the ligand-induced phosphoryl-
ation of IGF-IR and AKT in FA6 but not in the more re-
sistant BxPC3 cells (IC50= 1.54 μM) (Table 1, Figure 6).
We also investigated the growth response of these cancer
cell lines to treatment with PI3K and MAPKK inhibitorsand found that these were less effective compared to
afatinib and NVP-AEW541 (Figure 3, Table 1). Since the
IC50 values of these inhibitors for their respective targets
are below 2 μM (0.07 μM for MAPKK inhibitor, 1.4 μM
for PI3K inhibitor), our results suggest that the panel of
pancreatic cancer cell lines used in this study is highly re-
sistant to inhibition of PI3K and MAPKK.
We next assessed the anti-tumour activity of these
agents when used in combination. There was no im-
provement in anti-tumour activity when NVP-AEW541
was used in combination with mAb ICR62 (data not
shown). Treatment with a combination of gemcitabine
and NVP-AEW541 resulted in synergistic growth inhib-
ition only in PANC1 cell line (Table 2). Interestingly,
treatment with a combination of NVP-AEW541 and
afatinib was found to be superior, leading to a synergistic
growth inhibition of all pancreatic cancer cells with the
exception of PT45 which was the most resistance cell
line to treatment with NVP-AEW541 (Table 2). Synergism
following treatment with a combination of NVP-AEW541
and HER inhibitors (e.g. trastuzumab, erlotinib) has previ-
ously been reported in studies involving breast and colo-
rectal cancer cells [36,40,41].
Investigation of the effect of IGF-IR ligands (IGF-I,
IGF-II and Insulin) and HER ligands EGF and NRG-1
on the downstream signaling in BxPc3 cells revealed that
EGF primarily induces phosphorylation of MAPK while
IGF-IR ligands activate predominantly the PI3K/AKT
pathway. The activation of different pathways by the
Figure 6 Effect of IGF-I, IGF-II, Insulin, EGF and NRG-1 at in the presence or absence of IGF-IR and/or HER inhibitors (400 nM) in BxPc3
(A) or FA6 (B) cell line (overnight starved). Cells were grown to near-confluency in 10% FBS growth medium, then treated with the inhibitors
in 0.1% FBS growth medium at 37°C. Following 24 h incubation with the inhibitors or growth medium alone cells were stimulated with 20 nM of
various growth factors for 15 min. Cells were lysed , protein samples were separated by SDS-PAGE, transferred onto PVDF membranes and
probed with the antibodies of interest. C). Effect of afatinib (400 nM) and NVPAEW541 (400 nM) when used alone or in combination in BxPc3
cells in 10% FBS growth medium.
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gistic effect exhibited by the combination of pan-HER
blocker afatinib and IGF-IR inhibitor in this cell line. In op-
timal growth conditions (10% FBS supplemented medium)
afatinib was more potent at down regulating both AKT
and MAPK basal phosphorylation levels while NVP-
AEW541 downregulated pAKT but had no effect on
pMAPK basal levels in BxPc3 cells. However, even though
afatinib was more effective at downregulating pAKT thanNVP-AEW541, only the combination of NVP-AEW541
with afatinib led to complete loss of AKT phosphorylation
(Figure 6C).
In order to determine whether the diverse activation
of AKT and MAPK pathways by EGFR and IGF-IR acti-
vation could explain the synergism exhibited by the
same combination in the rest of the cell lines we
determined the effect of EGF and IGF on the phosphor-
ylation of AKT and MAPK in all cell lines included in
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the pattern of AKT and MAPK activation in all the other
pancreatic cells was found to be similar to BxPc3 cells
(Figure 5); EGF predominantly led to the activation of
MAPK whereas IGF treatment increased mainly the
phosphorylation of AKT but had low or no effect on
phosphorylation of MAPK. This in turn suggests that
the synergistic effect by this combination may be driven
by more effective and simultaneous blockade of HER
family members and IGF-IR induced phosphorylation of
both AKT and MAPK. However, further studies investi-
gating the effect of this combination in other signaling
pathways such as the JAK-STAT pathway, and the effect
of the mutational status of downstream cell signalling
molecules (e.g. IRS, PTEN and K-ras), on the synergistic
potential of this combination, are necessary in order to
elucidate the exact mechanism involved in the synergism
observed by this combination.
All of the pancreatic cancer cell lines examined in this
study were found to be IGF-IR positive, and in the ma-
jority of the cases, the expression levels were similar to
that of the IGF-IR positive MCF-7 control cell line con-
sequently, there was no correlation between IGF-IR ex-
pression and response to treatment with NVP-AEW541,
indicating that additional factors are implicated in the
sensitivity of these cell lines to IGF-IR inhibition
(Table 1). Lack of any clear association between IGF-IR
expression and response to NVP-AEW541 has also been
found in previous studies investigating the effect of this
agent against colorectal and breast cancer cell lines
[35,42].
In order to investigate the dependency of each cell line
to the HER and IGF-IR signalling pathways, we
determined the growth response of these cell lines to
several exogenous HER and IGF-IR ligands. Results
showed that while the majority of cell lines did not re-
spond to treatment with exogenous HER ligands, several
cell lines demonstrated increased growth following treat-
ment with IGF-IR ligands (BxPc3, AsPc-1, Capan-1 and
PT45) indicating that IGF-IR may have a more import-
ant biological role in this panel of pancreatic cancer cell
lines. In addition, the fact that two cell lines (AsPc-1 and
Capan-1) responded to some HER ligands but not others
(e.g. AsPc-1 responded to epigen treatment only but not
to any other EGFR ligand) indicates that different
ligands can have a diverse impact on the proliferation of
each pancreatic cancer cell line (Figure 2). Furthermore,
our results suggest that there is no correlation between
growth response to these exogenous ligands and inhib-
ition of their respective receptors. For example, FA6 cell
line which exhibited the highest sensitivity to IGF-IR in-
hibition (IC50 = 342 nM) by TKI NVP-AEW541, was
growth stimulated by 5-7% following treatment with ei-
ther IGF-I, IGF-II or insulin. In contrast, BxPc3, whichis a more resistant cell line to IGF-IR inhibition (IC50 =
1.54 μM), exhibited more than 30% increase in growth
following treatment with the same ligands (Figure 2).
Therefore, other factors such as the level of autocrine
ligands, the expression and status of downstream cell
signalling molecules, as well as the level of cross-talk be-
tween different RTKs may influence sensitivity to IGF-IR
inhibition [8,43].
Several studies investigating the therapeutic potential
of IGF-IR inhibition have been met with disappointing
results, indicating that the potential of this receptor as a
single target may be rather limited [44]. Interestingly,
our results show that NVP-AEW541 is effective at
inhibiting the growth of human pancreatic tumour cells
and that the combination of NVP-AEW541 and afatinib
is superior in terms of synergistic effect to the combin-
ation of either agent with gemcitabine. Taken together,
our findings encourage further investigation in vivo on
the therapeutic potential of this combination in pancre-
atic cancer.
Conclusion
Our results indicate that co-targeting of the erbB (HER)
family and IGF-IR, with a combination of afatinib and
NVP-AEW541, is superior to treatment with a single
agent and encourages further investigation on their
therapeutic potential in IGF-IR and HER positive pan-
creatic cancers.
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